Octreotide Injection

342 interactions 555 cited references

Also sold as: Bynfezia Bynfezia® Mycapssa Sandostatin Sandostatin® Sandostatin® LAR Depot

About Octreotide Injection

Octreotide immediate-release injection is used to decrease the amount of growth hormone (a natural substance) produced by people with acromegaly (condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) who cannot be treat… Read the full Octreotide Injection drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dronedarone Levoketoconazole Levomethadyl Mesoridazine Pimozide Ziprasidone

13 Contraindicated 325 Major 4 Moderate

All (342) Contraindicated (13) Major (325) Moderate (4)

Major

Octreotide Injection Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Octreotide Injection Dexlansoprazole Dexilant Decreased octreotide bioavailability Details Octreotide Injection Dexmedetomidine Dexased Increased risk of cardiac arrhythmias Details Octreotide Injection Dibenzepin An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Dienogest Decreased bioavailability and decreased efficacy of combined oral contraceptives or increased breakthrough bleeding Details Octreotide Injection Digoxin Cardoxin® Decreased digoxin exposure Details Octreotide Injection Dihydroergotamine Brekiya Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Dihydroxyaluminum Aminoacetate Decreased octreotide bioavailability Details Octreotide Injection Dihydroxyaluminum Sodium Carbonate Decreased octreotide bioavailability Details Octreotide Injection Disopyramide Norpace An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Docetaxel Beizray Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Dofetilide Tikosyn An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Dolasetron Anzemet An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Domperidone Increased risk of QT interval prolongation Details Octreotide Injection Donepezil Adlarity Increased risk of QT-interval prolongation and torsade de pointes Details Octreotide Injection Dordaviprone An increased risk of QT interval prolongation Details Octreotide Injection Doxepin Prudoxin An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Droperidol An increased risk of QT interval prolongation Details Octreotide Injection Drospirenone Decreased bioavailability and decreased efficacy of combined oral contraceptives or increased breakthrough bleeding Details Octreotide Injection Dulaglutide Trulicity An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Efavirenz An increased risk of QT interval prolongation Details Octreotide Injection Empagliflozin Glyxambi® (as a combination product containing Empagliflozin and Linagliptin) An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Encainide An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Encorafenib Braftovi Increased risk of QT interval prolongation Details Octreotide Injection Enflurane An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Entrectinib Rozlytrek An increased risk of QT interval prolongation Details Octreotide Injection Ergotamine Ergomar Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Ertugliflozin Steglatro An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Erythromycin Erythrocin Stearate Increased risk of QT interval prolongation Details Octreotide Injection Escitalopram Lexapro An increased risk of QT interval prolongation Details Octreotide Injection Esomeprazole Nexium Decreased octreotide bioavailability Details Octreotide Injection Estradiol Delestrogen Decreased bioavailability and decreased efficacy of combined oral contraceptives or increased breakthrough bleeding Details Octreotide Injection Ethinyl Estradiol Decreased bioavailability and decreased efficacy of combined oral contraceptives or increased breakthrough bleeding Details Octreotide Injection Ethopropazine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Ethynodiol Decreased bioavailability and decreased efficacy of combined oral contraceptives or increased breakthrough bleeding Details Octreotide Injection Etrasimod Velsipity Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Octreotide Injection Everolimus Afinitor Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Exenatide Bydureon An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Famotidine Calmicid Decreased octreotide bioavailability Details Octreotide Injection Fentanyl Increased exposure of CYP3A4 substrates with narrow therapeutic index Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.